

Why carry out this study?

- Economic modeling based on ISPOR guidelines requires standard approaches regardless of country or region.
- When models are based on clinical trials, country-specific costs and supportive care treatment patterns may influence results.
- This study was designed to conduct cost analyses on the same trial in two regions and compare the outcomes.

What was learned from the study?

- This comparison of a US and Japan economic model based on the PRONOUNCE lung cancer randomized trial showed consistent findings, despite the differences in health care systems and payment structures of the two countries
- Factors that vary across jurisdictions, even when minor, can have an impact on trial-based economic analyses.

This summary slide represents the opinions of the authors. This research project was funded by Eli Lilly and Company with support to RTI Health Solutions and to PRIMA Consulting Group for the development of the US and Japan economic models, respectively. For a full list of acknowledgments and disclosures for all authors of this article, please see the full text online. © The Author(s) 2015. Creative Commons Attribution Noncommercial License (CC BY-NC).